Sun Yat-sen University: Lung Neoplasms trials

The registry lists 85 Lung Neoplasms studies with Sun Yat-sen University as lead sponsor. 19 are open to participants now and 4 have results posted.

Phase 1 9Phase 2 53Phase 3 9Phase 4 2No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLCNot yet recruitingNCT07874464Phase 2
• Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07463677Phase 2
• A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07103395Phase 2
• PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLCRecruitingNCT06977074Phase 2
• Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）RecruitingNCT06924398Phase 2
• Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung CancerRecruitingNCT06730295Phase 2
• Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular CarcinomaRecruitingNCT06644430
• Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung CancerNot yet recruitingNCT06614231Phase 2
• Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain MetastasisRecruitingNCT06582940Phase 2
• Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingNCT06563999Phase 2
• Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary MetastasesRecruitingNCT06265350Not applicable
• Effects of Digital Therapeutic in Whole Process Management of Lung CancerRecruitingNCT06230445Phase 3
• Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2
• Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTRecruitingNCT05623267Phase 2/3
• Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation TherapyRecruitingNCT05468242Phase 2
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
• Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCRecruitingNCT05011487Phase 2
• Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLCRecruitingNCT03872661Phase 2
• A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients TreatmentRecruitingNCT01994057
• CAR-T Cell Immunotherapy for Advanced Lung CancerTerminatedNCT03330834Phase 1Results posted
• Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedNCT02264210Phase 2Results posted
• Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung CancerStatus unknownNCT01218594Phase 2Results posted
• Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung CancerCompletedNCT01194453Phase 2Results posted
• Prognostic Significance of the Uncertain Resection in NSCLCActive, not recruitingNCT06511661
• Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy EffectivenessCompletedNCT06292052
• Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).WithdrawnNCT06227897Phase 2
• Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung CancerWithdrawnNCT05481775Phase 2
• Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung CancerCompletedNCT05226728Phase 1
• Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesStatus unknownNCT05207904Phase 2
• Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung CancerStatus unknownNCT05016544Phase 1/2
• A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With OligoprogressionStatus unknownNCT04970693Phase 2
• Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLCCompletedNCT04951063Phase 1
• MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung CancerCompletedNCT04946019Phase 2
• Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.Status unknownNCT04722406
• Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent ChemoradiotherapyCompletedNCT04654234
• Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLCStatus unknownNCT04524299Phase 2
• Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung CancerStatus unknownNCT04397926Phase 1
• Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLCCompletedNCT04345146Phase 2
• Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung CancerStatus unknownNCT04275687Phase 2
• Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following ResectionCompletedNCT04238130
• Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT04213170Phase 2
• Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung CancerCompletedNCT04212052Phase 2
• Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLCStatus unknownNCT04211090Phase 2
• A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCStatus unknownNCT04167774Phase 2
• Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT04153799Phase 1
• Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation TherapyActive, not recruitingNCT04085250Phase 2
• Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLCStatus unknownNCT04028778Phase 3
• A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung CancerStatus unknownNCT03903887Phase 1/2
• Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLCCompletedNCT03900117Phase 2
• Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung CancerCompletedNCT03673657Phase 2
• Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung CancerTerminatedNCT03661567Phase 2
• Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung CancerCompletedNCT03659578Phase 2
• Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCStatus unknownNCT03527251Phase 1
• Osimertinib as First-line Therapy for Patients With Late-stage Lung CancerStatus unknownNCT03460275Phase 2
• A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain MetastasesStatus unknownNCT03257735
• ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGSCompletedNCT03172156
• APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLCWithdrawnNCT03164694Phase 2
• Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung CancerStatus unknownNCT03006575Phase 2
• Detection Cell Free DNA in Lung Cancer PatientsStatus unknownNCT02738593
• Paclitaxel Detection in NSCLC Treated With TC RegimenTerminatedNCT02737709Phase 2
• EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLCStatus unknownNCT02714010Phase 3
• An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer PatientsStatus unknownNCT02708667
• Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus TreatmentCompletedNCT02646020Phase 2
• A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI FailureStatus unknownNCT02618590
• A Prospective, Observational Trial on the Diagnostic and Prognostic of LMStatus unknownNCT02607605
• Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung CancerCompletedNCT02577341Phase 2
• Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung CancerCompletedNCT02573506Phase 2
• IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain MetastasesTerminatedNCT02556593Phase 2
• Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung CarcinomaWithdrawnNCT02428764Phase 2
• NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.WithdrawnNCT02347839Phase 2
• Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung CancerStatus unknownNCT02337712Phase 2
• Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung CancerStatus unknownNCT02274337Phase 1/2
• Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR MutationTerminatedNCT01996098Phase 3
• Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant NsclcStatus unknownNCT01955421Phase 2
• Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT01951469Phase 3
• the Quality of Life Assessment of Lung Cancer Patients in ChinaStatus unknownNCT01914120
• Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing StrategyStatus unknownNCT01891123Not applicable
• Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC PatientsStatus unknownNCT01882621Phase 3
• CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT01533727Phase 2
• Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLCCompletedNCT01528488Phase 2/3
• Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung CancerStatus unknownNCT01287962Phase 3
• A Trial on Video-assisted Thoracoscopic Surgery and Axillary Thoracotomy for Resection of Early-stage Non-small Cell Lung CancerStatus unknownNCT01102517Not applicable
• A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of LungCompletedNCT00816868Phase 2
• Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving BisphosphonatesCompletedNCT00765687Phase 4
• Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone MetastasisCompletedNCT00762346Phase 4